Trial Profile
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ricolinostat (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 21 May 2021 Results assessing computational network-based algorithm to evaluate the activity of the HDAC6 protein, presented at the 112th Annual Meeting of the American Association for Cancer Research.
- 05 Jan 2021 Status changed from active, no longer recruiting to completed.
- 28 Apr 2020 Results assessing safety and tolerability of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer , presented at the 111th Annual Meeting of the American Association for Cancer Research - I